Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109

9518447302
|
Calling
Whatsapp
Get in touch

Home /All Blogs /understanding-the-scheme-system-in-pharma-sales

The Real Dirt on Pharma Schemes: How to Actually Move Product Without Killing Your Margin

look, if you’re actually out there grinding in the **pharmaceutical sales** trenches, you already know it’s a straight-up bloodbath. Navigating the whole **scheme system** isn’t some boring HR checkbox you can just ignore; it’s literally the only way you survive without getting laughed out of the room by a chemist who's seen it all. Any **sales manager** who isn't a total rookie knows that fixing the **supply chain** is about way more than just having a drug that actually works—it’s about this weird, almost pathological obsession with **trade margins** and how fast that inventory is actually turning over. You want to see **revenue growth** that doesn't just look cute on a PowerPoint slide but actually hits the bank? You better learn to juggle **stockist margins** and **GST compliance** without losing your **competitive advantage** or your mind. Throwing a **volume-based discount** or some flashy **retail incentives** at the wall can absolutely set your **secondary sales** on fire, and honestly, that’s the only thing the **P&L** and **ROI** people care about anyway. By dissecting the **product lifecycle**, you can tweak your **pharma distribution** using **primary sales** targets, **cash discounts**, and those "free" goods—yeah, the classic 10+1. At the end of the day, winning **market share** in this business is about mastering **sales force effectiveness** and getting down into the weeds of **net-net pricing**. This guide is gonna look at the guts of these schemes, moving past basic math to show the weird financial engineering that actually runs the global drug trade. Seriously.

The Anatomy of a Pharma Scheme: It’s Not Just a Discount, It’s Chess

In this industry, a "scheme" isn't just some polite price drop. It’s a psychological hammer you pull to make people move. Unlike the grocery business (FMCG) where people see a TV ad and go buy a soda, pharma is all about the "Trade Push." You basically have to bribe the channel to give a damn. We do this through **Quantity Purchase Schemes (QPS)**—basically, "buy a mountain of this, and I'll make it worth your while." The 10+1 or 10+2 models are the bread and butter here. Sure, the math is close to a percentage discount, but the vibe is totally different. When a chemist gets 12 units but only pays for 10, their **Price to Retailer (PTR)** looks stable on the official invoice, but they’re holding two units that represent 100% pure profit when sold. This kind of inventory loading is GREAT for the manufacturer because it literally blocks the shelf. If the retailer’s backroom is full of your stuff, they don't have the cash or the space to buy your competitor’s product. Simple as that. No joke.

Margin Compression: Living in the "Net-Net" Reality

Statutory margins are usually a total joke. Look at the **statutory margins**—in a lot of places, they try to cap wholesalers at 8% and retailers at 16%. But seriously, who can live on that in a hyper-competitive market? NOBODY. That’s why we have schemes. They’re the secret trapdoor to bypass those ceilings. By stacking trade discounts and freebies, companies effectively juice those wholesaler margins up to 12-15% and give retailers a fat 25-30%. This "margin expansion" is the only way to move **generic drugs** where nobody cares about the brand and the guy behind the counter is just gonna swap your product for whatever gives him a better kickback. Your **Effective Net Price**—the real cost after every single bribe and incentive is subtracted—is the only metric that matters. If you aren't watching that "Net-Net" number, your gross margins are gonna evaporate while you're busy celebrating "increased volume." Smart operations are now using **real-time data** to check the **Contribution Margin** of a scheme before they even let the sales reps open their mouths. i think that's the only way to stay profitable.

The Messy Truth About Primary and Secondary Sales

You HAVE to know the difference between **primary sales** (selling to the distributor) and **secondary sales** (distributor selling to the shop). It’s the difference between a healthy business and a total dumpster fire. Primary schemes are usually just about **liquidity management**—clearing out the warehouse to hit quarterly numbers so the boss stays happy. But if those primary sales aren't moving out the back door as secondary sales, you’re just "channel stuffing." That’s how you end up with massive **inventory days** and, eventually, a nightmare of **stock dumping** or returns. To keep things moving, you use secondary schemes. The manufacturer pays for them, but the distributor runs them. These are often "Value-based" deals, where you reward a chemist for **everything you sell**, not just one drug. It keeps the **market hygiene** clean and stops those localized price wars that happen when one guy gets a massive discount and starts "dumping" product into the next town over. Seriously, it's a mess if you don't track it.

Get in Touch

Using Schemes as a Weapon Throughout the Product Lifecycle

You can't use the same scheme forever. It’s gotta evolve. During a **New Product Launch**, it’s all about "stocking." You might see schemes as crazy as 1+1 because you just need the product to exist in every pharmacy. Who cares about profit in month one? You want visibility. Once you hit the **Growth Phase**, you switch to **Volume-Based Schemes**. Tier that stuff—"Buy 50 boxes for 10% off, buy 100 for 15%." Reward the big players. By the time you’re in the **Maturity Phase**, you’re just playing defense against new guys. And when the product is in the **Decline or Near-Expiry Phase**? That’s when it gets aggressive. With maybe 3-5% of **pharma stock** coming back as expired junk, you better run a "Liquidation Scheme" six months before the date. Trust me, selling it at a 50% discount right now is way better than paying for **reverse logistics** and the cost of burning it later. TOTAL LOSS is not an option. Period.

The Weird Logic of 10+2 and Why it Works

The data doesn't lie: products with a "10+2" deal move **40% faster** than those with a flat discount. Why? Because of "inventory pressure." If a chemist is staring at a stack of boxes in his small shop, he’s gonna find a way to sell them. He’ll recommend them to patients or put them right at the front of the counter. This speed reduces the "Days Sales Outstanding" (DSO) and makes the whole **cash-to-cash cycle** actually work for the manufacturer. But—and this is a big but—you have to watch out for "Scheme Leakage." This is when the distributor is a snake and pockets part of the scheme. If you offer a 10+2 deal but the distributor only tells the chemist it’s a 10+1, the distributor just stole your margin and killed your market push. This is why everyone is moving to B2B apps now—to make sure the chemist actually knows what they’re supposed to be getting. Knowledge is power, or whatever.

The Ugly Side: Gray Markets and Infiltration

Schemes are powerful, but they can blow up in your face. **Market Infiltration** is the big one. If you run a killer deal in one state but not the neighboring one, your distributors are gonna start "cross-border" selling. They’ll buy a truckload in the cheap zone and dump it in the expensive one. It creates a "gray market" that makes your local reps want to quit and messes up your pricing everywhere. Plus, if **secondary sales** don't keep up with your loaded inventory, the **breakage and expiry returns** will skyrocket. The cost of shipping that stuff back and destroying it often wipes out every cent of profit you thought you made. A real expert uses a "Net-Net-Net" math: Revenue minus Discounts, minus Tax, minus the projected cost of all that junk coming back in six months. It's the only way to stay sane.

Cash vs. Trade Discounts: It’s All About the Benjamins

People get **Trade Discounts (TD)** and **Cash Discounts (CD)** mixed up all the time. A TD is just a price cut to stay competitive. But a CD? That’s a reward for paying the bill early—like 2% off if they settle in 7 days. When interest rates are high, CD is king. For a pharma company, getting that cash 30 days sooner is worth way more than that 2% margin. It keeps you from needing bank loans and makes your **current ratio** look sexy. But watch the **GST compliance**! In a lot of places, if that discount isn't tied to an agreement you made *before* the sale, the tax man won't let you deduct it, and you'll end up paying tax on money you never actually got. It’s a total nightmare if you don’t track it perfectly.

The Taxman Cometh: Regulatory Nightmares

Nowadays, the auditors are obsessed with pharma schemes. Under GST or VAT, "free goods" aren't actually free. The government still wants their cut. Usually, you have to show a "Trade Discount" on the invoice that covers the value of the free stuff so you’re only paying tax on the **net taxable value**. If you mess this up, your **Input Tax Credit (ITC)** could get yanked. A lot of companies are moving to "Post-Supply Discounts" using credit notes, but the paper trail is a nightmare. You have to prove the discount actually reached the retailer. If you don't, you’re looking at "Tax Leakage," which is basically just flushing money down the toilet. Sales managers now have to be part-time tax man just to run a simple "Buy 10, Get 1" promo. No joke.

What’s Next? Robots and Personalization

We’re moving away from big, dumb, blanket schemes. The future is **Targeted Incentives**. Using **CRM data** and some AI magic, companies are starting to give personalized deals to specific shops based on how they pay and what they sell. Instead of 10% for everyone, maybe you give 15% only to the "A-Category" guys who never return expired stock. There’s also a huge move toward "Net Pricing"—basically just one low, honest price with no schemes. It makes **GST compliance** easy and stops the gray market, but you lose that "psychological hit" of the free boxes. The winners in the next few years are gonna be the ones who can balance the old-school power of the scheme with new-school data. If you want to own the **pharma sales** world, you better master the scheme. it's basically the only way forward.

The Cheat Sheet: Scheme Types and What They Actually Do

Scheme Name Who it’s For The Goal The Damage (P&L)
Quantity Purchase (QPS) The Whole Chain Forcing volume into the market; blocking competitors. Crushes Gross Margin but inflates volume stats beautifully.
Secondary Scheme The Chemist Getting them to actually sell it to a human being. Pure marketing cost; keeps the stock moving so it doesn't rot.
Cash Discount (CD) Stockists Getting paid before the heat death of the universe. Cheaper than a bank loan; keeps the current ratio looking sexy.
Liquidation Scheme Retailers Dumping stock before it becomes toxic waste or expired junk. Sucks for the bottom line, but way better than a 100% loss.
Youtube Cafoli Lifecare

Common Questions from the Field

Q1: Why not just give a 10% discount instead of 10+1?
A: Math nerd answer: 10+1 is an 11-unit deal for the price of 10, so it’s actually a 9.09% discount. It’s cheaper for the company than a flat 10%. Plus, you moved 10% more physical boxes. More boxes on shelves = more **market share**. Simple as.

Q2: How bad is "Scheme Leakage" really?
A: It’s a silent killer. If your distributor steals the scheme, you’re losing margin for zero benefit. You’re basically just giving the distributor a bonus to let your product sit in their warehouse and gather dust. It’s "dead cost." Avoid it like the plague.

Q3: Can’t we just lower the MRP?
A: No way. MRP is usually regulated—once you drop it, you can almost never raise it again. Also, a high MRP with a deep scheme means a bigger profit per unit for the chemist. If the chemist makes more money on your brand than the other guy’s, guess which one he’s gonna recommend? Greed works. ALWAYS.

Q4: Is GST on free goods a real problem?
A: Huge. The tax man doesn't believe in "free." You have to document the discount perfectly on the invoice so the **net taxable value** is right. If you don't, you'll get hit with an audit that’ll make your head spin. Seriously, no joke.

Q5: What happens if I "Over-Scheme" a product?
A: You kill the brand. People start thinking the "discount price" is the real price. You destroy the **distribution hygiene**, and pretty soon, your product is being dumped in other territories and your margins are in the gutter. It's a race to the bottom. Don't do it.

Explore Similar Options